ARF and p53 are commonly inactivated whereas Mdm2 is overexpressed in a majority of B-cell lymphomas in patients [38]–[40], and genetically engineered mice that mimic those alterations effectively model the disease [41]–[43]. This evidence concerns the gene CDKN2A and B-cell non-Hodgkin lymphoma.